Novartis CEO holds larger acquisitions possible
For three years, the Novartis leadership formed by the pharmaceutical giants. But not everything is running smoothly. To further catch up to CEO Joe Jimenez can imagine even larger acquisitions.
The pharmaceutical giant Novartis can again imagine larger acquisitions. "A takeover worth more than five billion dollars, I do not rule out," said Novartis CEO Joe Jimenenz towards "balance", "but in this case must be immediately visible their strategic and financial logic."
Previously, management had primarily spoken of supplementary acquisitions worth up to five billion dollars. Facing possible targets Jimenez thinks less of the cancer business, although analysts Novartis a lag in the immune oncology certify .: "There are in addition to the immune oncology a number of other regions in which acquisitions are conceivable, such as immunology or even the generic business, "says Jimenez.